XTX Topco Ltd Acquires Shares of 20,669 Kura Oncology, Inc. (NASDAQ:KURA)

XTX Topco Ltd bought a new position in Kura Oncology, Inc. (NASDAQ:KURA) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 20,669 shares of the company’s stock, valued at approximately $180,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Harbor Advisors LLC purchased a new stake in shares of Kura Oncology in the 4th quarter worth about $87,000. E Fund Management Co. Ltd. purchased a new stake in shares of Kura Oncology in the 4th quarter worth about $90,000. Optimize Financial Inc purchased a new stake in shares of Kura Oncology in the 4th quarter worth about $100,000. Corient Private Wealth LLC purchased a new stake in shares of Kura Oncology in the 4th quarter worth about $109,000. Finally, Teacher Retirement System of Texas grew its position in shares of Kura Oncology by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock worth $120,000 after buying an additional 2,285 shares during the period.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. StockNews.com raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research report on Friday, April 4th. Wedbush reissued an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a research report on Tuesday, April 8th. UBS Group cut their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Finally, Cantor Fitzgerald raised shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $25.50.

Kura Oncology Trading Up 1.2 %

Shares of KURA stock opened at $6.51 on Tuesday. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $23.48. The firm has a fifty day moving average price of $6.85 and a 200-day moving average price of $9.85. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company has a market cap of $525.86 million, a price-to-earnings ratio of -2.76 and a beta of 0.83.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. As a group, equities analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.